Efficacy of interferon treatment (IFN) in elderly patients with chronic hepatitis C

Infezioni in Medicina

Volumn 11, Issue 4, 2003, Pages 208-212

  Alessi, Nunziata ^a   Freni, Maria Antonietta ^a   Spadaro, Aldo ^a   Ajello, Antonino ^a   Turiano, Santi ^a   Migliorato, Domenico ^a   Ferraù, Oscar ^a  

^a UNIVERSITY OF MESSINA   (Italy)

Author keywords

Aged patients; Chronic hepatitis C; Interferon treatment

Indexed keywords

ALPHA INTERFERON;

ADOLESCENT; ADULT; AGE; AGED; ARTHRALGIA; ARTHROMYALGIA; ARTICLE; ASTHENIA; BIOCHEMISTRY; CHI SQUARE TEST; DRUG EFFECT; DRUG EFFICACY; DRUG RESPONSE; DRUG TOLERABILITY; FEMALE; FEVER; FISHER EXACT TEST; GENOTYPE; HEPATITIS C; HISTOGENESIS; HUMAN; INSOMNIA; LEUKOPENIA; LIVER CIRRHOSIS; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MORALITY; MYALGIA; RASH; SIDE EFFECT; STUDENT T TEST; THROMBOCYTOPENIA;

ADOLESCENT; ADULT; AGE FACTORS; AGED; ANTIVIRAL AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; INTERFERON-ALPHA; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; SAFETY; TREATMENT OUTCOME;

EID: 0742271041     PISSN: 11249390     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (16)

1. Purcell R.H. The discovery of the hepatitis viruses. Gastroenterology 104, 955-963, 1993.
2. Wasley A., Alter M.J. Epidemiology of hepatitis C: geographic differences and temporal trends. Semin. Liver Dis. 20, 1-16, 2000.
3. Rubin R.A., Falestiny M., Malet P.F. Chronic hepatitis C: Advances in diagnostic testing and therapy. Arch. Intern. Med. 154, 387-392, 1994.
4. Manns M.P., Mc Hutchinson J.G., Gordon S.C. et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 358, 958-965, 2001.
5. [5)] Conjeevaram H.S., Everhart J.E., Hoofnagle J.H. Predictors of a sustained beneficial response to interferon alpha therapy in chronic hepatitis C. Hepatology 22, 1326-1329, 1995.
6. Causse X., Godinot H., Chevallier M. et al. Comparison of 1 or 3 MU of interferon alpha 2b and placebo in patients with chronic non-A, non-B hepatitis. Gastroenterology 101, 497-502, 1991.
7. Serfaty L., Giral P., Loria A., Andreani T., Legendre C., Poupon R. Factors predictive of the response to interferon in patients with chronic hepatitis C. J. Hepatol. 21, 12-17, 1994.
8. Jouet P., Roudot-Thoraval F., Dhumeaux D., Metreau J.M. Comparative efficacy of interferon alpha in cirrhotic and non-cirrhotic patients with non-A, non-B, C hepatitis. Le Groupe Francais pour l'Etude du Traitement des Hepatites Chroniques NANB/C. Gastroenterology 106, 686-690, 1994.
9. Terranova R., Luca S. Preliminary results of beta-interferon treatment in the elderly. Controlled Clin. Trials 17, 123-129, 1996.
10. Van Thiel D.H., Friedlander L., Caraceni P., Molloy P.J., Kania R.J. Treatment of hepatitis C in elderly persons with interferon alpha. J. Gerontol. Biol. Sci. Med. Sci. 50, M 330-333, 1995.
11. Pawlotsky J.M., Roudot-Thoraval F., Bastie A. et al. Factors affecting treatment responses to interferon-alpha in chronic hepatitis C. J. Infect. Dis. 174, 1-7, 1996.
12. Mita E., Hayashi N., Hagiwara H. et al. Predicting interferon therapy efficacy from hepatitis C virus genotype and RNA titer. Dig. Dis. Sci. 39, 977-982, 1994.
13. Magrin S., Craxi A., Fabiano C. et al. HCV viremia is more important than genotype as a predictor of response to interferon in Sicily (Southern Italy). J Hepatol. 25, 583-590, 1996.
14. Gordon S.C., Kodali V.P., Silverman A.L. et al. Levels of hepatitis C virus RNA and liver histology in chronic type C hepatitis. Am. J. Gastroenterol. 89, 1458-1461, 1994.
15. Nishiguchi S., Kuroki T., Nakatani S. et al. Randomised trial of effects of interferon alpha on incidence of hepatocellular carcinoma in chronic active hepatitis C with cirrhosis. Lancet 346, 1051-1055, 1995.
16. Di Bisceglie A.M., Hoofnagle J.H. Optimal therapy of hepatitis C. Hepatology 36 S2, S121-S127, 2002.